Organon (OGN) Stock Dips While Market Gains: Key Facts
The latest trading day saw Organon (OGN) settling at $9.96, representing a -1.87% change from its previous close.
OGN vs. MEDP: Which Stock Is the Better Value Option?
Investors interested in Medical Services stocks are likely familiar with Organon (OGN) and Medpace (MEDP). But which of these two stocks offers value investors a better bang for their buck right now?
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Organon (OGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Organon: A Look Beyond The Dividend Cut
Organon stock is deeply undervalued after a 70% decline and a sharp dividend cut, now trading at just 2.6x forward PE. Growth headwinds in established brands are offset by strong momentum in biosimilars and women's health, particularly Nexplanon. Management's focus has shifted to aggressive debt reduction, suspending shareholder rewards, which is the need of the hour.
All You Need to Know About Organon (OGN) Rating Upgrade to Buy
Organon (OGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
OGN or DOCS: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical Services sector might want to consider either Organon (OGN) or Doximity (DOCS). But which of these two stocks presents investors with the better value opportunity right now?
Organon (OGN) Exceeds Market Returns: Some Facts to Consider
In the most recent trading session, Organon (OGN) closed at $10.19, indicating a +1.49% shift from the previous trading day.
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Organon & Co: Cost Takeout Catalysts, Initiate Strong Buy
Initiate Strong Buy on Organon & Co. with $26.4 PT, driven by cost savings, Nexplanon momentum, and biosimilars diversification offsetting Established Brands LOE. Forecasted EPS of $4.00 (FY25; +20.1% Y/Y) and $4.40 (FY26; +10.0%), well above consensus, supported by operational leverage and dividend cut for deleveraging. Transformational cost savings of >$200M by FY25 and $275M by FY26, driving margin expansion and multi-year EPS acceleration.
Organon: Management Slashes Dividend - This Feels Disastrous
Organon's Q1 2025 earnings report showed significant declines across key financial metrics, leading to a drastic 30% drop in share price following a >90% dividend cut. The company's revenue shrinkage is primarily due to declining sales in its Established Brands division, exacerbated by the patent expiry of key drugs. Management's rationale for cutting the dividend to manage debt and pursue M&A opportunities appears flawed, as it fails to address core financial issues.
Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
